Published by
@ShahidNShah
@ShahidNShah
8th Annual DDR Inhibitors Summit is held on 28-30 January 2025 in Boston, MA.AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors and innovative combination therapies. At the same time, Roche and Novartis are pushing their own DDR-targeting pipelines, exploring emerging targets such as USP1 and WRN - these combined efforts are making DDR inhibitor drug development an increasingly dynamic and transformative area.Additionally, biotechs like Artios Pharma and Repare Therapeutics are expanding the field with cutting-edge research and clinical programs, using innovative platforms to understand cancer biology, discover novel DDR targets, and identify patients most likely to benefit from the treatments.
[Read on ddr-inhibitors-summit.com](https://ddr-inhibitors-summit.com/take-part/register/)
Continue reading at ddr-inhibitors-summit.com
January 28 to January 30, 2025
Sheraton Frankfurt Airport Hotel and Conference Center, 15 Hugo-Eckener-Ring, Frankfurt am Main, Hessen, 60549, Germany
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 18, 2024 at 12:33pm